KIRKLAND, QC, Oct. 30, 2015 /CNW/ - Pfizer Canada Inc., the Canadian
distributor of EpiPen® and EpiPen® Jr (0.3 and 0.15 mg epinephrine)
Auto-Injectors, fully expects to meet the exceptional increase in
demand on the Canadian market resulting from the nationwide recall of
Sanofi's Allerject® (epinephrine injection, USP). The recall is
specific to the Allerject® epinephrine auto-injector, manufactured by
Sanofi and does not apply to EpiPen®.
Pfizer Canada has already shipped its current EpiPen® inventory to
wholesalers to be made available to Canadian patients.
Patient safety is Pfizer's top priority and we are working diligently to
secure and distribute five times our usual monthly EpiPen® inventory to
replace the Allerject® auto-injectors recalled from the market. We are
pleased to confirm that starting the first week of November, several
additional shipments of EpiPen® and of EpiPen® Jr will arrive in
Canada, which will be sufficient to meet the unexpected increase in
demand by month end.
EpiPen® and EpiPen® Jr (0.3 and 0.15 mg epinephrine) Auto-Injectors
("EpiPen") are indicated for the emergency treatment of anaphylactic
reactions in patients who are determined to be at increased risk for
anaphylaxis, including individuals with a history of anaphylactic
reactions. The EpiPen® Auto-Injector is a disposable, pre-filled
automatic injection device that administers epinephrine in the event of
a severe allergic reaction. After using EpiPen®, you must seek
immediate medical attention or go to the emergency room. For the next
48 hours, you must stay close to a healthcare facility or be able to
call 911. For more information about EpiPen®, please visit http://www.epipen.ca or you can follow us on Facebook (facebook.com/EpiPenCanada).
About Pfizer Canada
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the
world's leading biopharmaceutical companies. Our diversified health
care portfolio includes some of the world's best known and most
prescribed medicines and vaccines. At Pfizer, we're working together
for a healthier world. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).
EpiPen®, EpiPen® Jr are registered trademarks of Mylan, Inc. licensed exclusively to its
wholly-owned affiliate, Mylan Specialty, L.P.; sub-licensee, Pfizer
Canada Inc., Kirkland, Quebec H9J 2M5
SOURCE Pfizer Canada Inc.
Image with caption: "EpiPen® and EpiPen® Jr (epinephrine) Auto-Injectors (CNW Group/Pfizer Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20151030_C9127_PHOTO_EN_44356.jpg
For further information:
Pfizer Canada Inc.
1 866 9PFIZER (973-4937)